Abstract
Cancer Biotherapy and Radiopharmaceuticals officially retracts the paper entitled, “Targeted Regulation of FoxO3a by miR-372 to Mediate Gastric Carcinoma Cell Apoptosis and DDP Drug Resistance” by Changting Wang, Chunxiao Wang, Chengzhi Qiu, and Zhiming Su (Cancer Biother Radiopharm 2020;35(10):753–759; doi: 10.1089/cbr.2019.3299).
The published paper was flagged as a potential submission from a paper mill. In an effort to determine the paper's validity, the journal contacted the corresponding author, Dr. Changting Wang, and requested the raw data files as they pertained to the work. Dr. Wang was not able to provide the data and indicated via email, “Our experiment is still going on. At the end of the experiment, we will add the corresponding content as soon as possible.”
Dr. Wang's response is impermissible. As per customary practices of study protocols, raw data image files should be archived and readily available upon request. Conducting new experiments after the work has been published is not acceptable as it indicates that the results of the work may not be reproducible and renders the conclusions questionable.
The journal officially retracts the paper from the literature based on Dr. Wang's indication of ongoing experiments and inability to produce the raw data. This is a violation of standard protocols and is considered an infraction against the rigorous standards of scientific publishing.
The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves.
Get full access to this article
View all access options for this article.